-
2023
-
Future of generative AI in pharma
-
AstraZeneca says cancer drug Enhertu showed positive results
-
FDA Denies Petition to Grant Simufilam Breakthrough Designation
-
Merck’s MK-0616, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Patients with Hypercholesterolemia in Phase 2b Study
-
FDA Approves IM Administration of Merck’s MMRV Family of Vaccines
-
FDA Expands Approval of Eli Lilly’s Verzenio for High-Risk Early Breast Cancer
-
FDA Accepts Ionis NDA for Eplontersen in Rare Hereditary Disease
-
Tagrisso demonstrated strong overall survival benefit in the ADAURA Phase III trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
-
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in China
-
Despite FDA doubts, advisors back first-line Polivy use